Acetazolamide for Episodic Ataxia Type 2: Real Effectiveness, No Formal Approval
A single patient with genetically confirmed episodic ataxia type 2. The standard treatment has real, described effectiveness — it has just never been formally approved for this diagnosis.
L.P., a 19-year-old woman in her second year of college, has had episodes of vertigo, slurred speech, and truncal ataxia since age eleven, each lasting anywhere from twenty minutes to several hours, brought on reliably by stress, caffeine, and physical exertion — episodes bad enough during exams last semester that she missed two finals and had to petition for incompletes. Genetic testing, sent after a movement disorders specialist recognized the pattern, confirmed a pathogenic CACNA1A mutation, establishing episodic ataxia type 2, a channelopathy affecting the same P/Q-type calcium channel implicated in a related spectrum of disorders that includes some forms of migraine and a specific type of spinocerebellar ataxia.
Acetazolamide, a carbonic anhydrase inhibitor whose actual mechanism of benefit in EA2 isn't fully understood despite decades of clinical use, has been the standard first-line treatment for EA2 since Griggs et al. (1978) first described the response, and most patients in the published series do respond, some of them dramatically — though the literature also describes that response as variable, and the evidence behind it is case series and long clinical experience rather than randomized data. What acetazolamide does not have is a formal FDA indication for episodic ataxia; its approved indications are glaucoma, certain edematous states, altitude sickness, and as an adjunct for some seizure types, and its use in EA2 rests entirely on off-label clinical practice and published case experience rather than a labeled indication or a randomized trial specifically in this condition.
L.P.'s insurance initially denied coverage for acetazolamide, flagging the prescription as off-label for her diagnosis code. Her neurologist's office appealed with a letter citing the published literature, and won. The drug's effectiveness was never what was in dispute; what "no formal approval" cost her was three weeks and a letter.
After the insurance appeal was won
Start acetazolamide. It has been the standard first-line treatment for EA2 since Griggs et al. (1978) first reported the response, and most patients in the published series do respond, some of them dramatically. I'll be straight about what kind of evidence that is: case series and long clinical experience, not randomized data. The lack of a formal FDA indication reflects the rarity of the disease more than any failure of the drug — but I don't want to overstate it either, because the response is described as variable, and some patients simply don't get it.
I agree it's the reasonable place to start and I'm not arguing against it. But I'd push back on one thing you said — that there's nothing with comparable evidence. There actually is better evidence, for a different drug: Strupp et al. (2011) ran a randomized, double-blind, placebo-controlled crossover trial of 4-aminopyridine in ten patients with episodic ataxia, most genetically confirmed EA2, and monthly attacks fell from a median of 6.5 on placebo to 1.65 on 4-AP. That's Class II randomized evidence, which is a stronger tier than acetazolamide's case series, even though acetazolamide remains first-line by convention and tolerability. Separately, acetazolamide isn't free of real side effects — paresthesias, a genuine risk of renal calculi, metabolic acidosis with longer use — and she should understand she's being offered an effective but formally off-label treatment, not a routine on-label prescription.
Framing the lack of FDA approval as purely a technicality about trial feasibility undersells what it actually means for her day to day — exactly the insurance friction she already ran into, and a real conversation she deserves to have explicitly rather than have implied only by an approval-status footnote.
Both of those are right, and I don't think they're actually in tension. Start acetazolamide at a low dose specifically to gauge her individual tolerability before committing to a maintenance dose, with baseline renal function and electrolytes checked and a plan to recheck periodically given the metabolic acidosis and stone risk. And note 4-aminopyridine in her chart now as the named second-line option if acetazolamide fails or she can't tolerate it — that's exactly the situation Strupp's trial was designed to speak to, and it shouldn't have to be rediscovered a year from now.
And she should leave today with the off-label status explained plainly, in writing if useful for future insurance appeals or a future provider who doesn't know her history — not because the drug is a weak choice, it's the right one, but because she's an adult managing a rare disease who deserves to understand exactly what she's on and why insurance already tried to make that harder once.
Agreed: acetazolamide started at a low dose with a clear titration plan, baseline renal function and electrolytes checked, and a written summary of the off-label rationale provided for her own records and any future insurance appeals.
Not agreed: how explicitly “off-label” should be framed to a newly adult patient managing a rare disease for the first time on her own — the Clinical Pharmacologist wanted it stated plainly as a distinct conversation; the Neurologist worried that over-emphasizing the approval-status distinction risked making a genuinely well-supported, standard treatment sound more uncertain to her than the actual evidence justifies. Both approaches were used, without fully resolving which framing is right in general.